(Q51030667)

English

Pilot study of vincristine, oral irinotecan, and temozolomide (VOIT regimen) combined with bevacizumab in pediatric patients with recurrent solid tumors or brain tumors.

scientific article published on 29 April 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/23630159

Pilot study of vincristine, oral irinotecan, and temozolomide (VOIT regimen) combined with bevacizumab in pediatric patients with recurrent solid tumors or brain tumors. (English)

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/23630159

1 reference

based on heuristic

inferred from title

0 references

1 reference

based on heuristic

inferred from title

author name string

Lars Wagner

1

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/23630159

Brian Turpin

2

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/23630159

Rajaram Nagarajan

3

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/23630159

Brian Weiss

4

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/23630159

Timothy Cripe

5

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/23630159

James Geller

6

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/23630159

publication date

29 April 2013

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/23630159

Pediatric Blood Cancer

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/23630159

60

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/23630159

9

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/23630159

1447-1451

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/23630159

Irinotecan and temozolomide for Ewing sarcoma: the Memorial Sloan-Kettering experience

1 reference

https://api.crossref.org/works/10.1002%2FPBC.24547

21 January 2018

Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma

1 reference

https://api.crossref.org/works/10.1002%2FPBC.24547

21 January 2018

Phase II study of irinotecan and temozolomide in children with relapsed or refractory neuroblastoma: a Children's Oncology Group study

1 reference

https://api.crossref.org/works/10.1002%2FPBC.24547

21 January 2018

Extended phase I evaluation of vincristine, irinotecan, temozolomide, and antibiotic in children with refractory solid tumors.

1 reference

https://api.crossref.org/works/10.1002%2FPBC.24547

21 January 2018

Clinical development of VEGF signaling pathway inhibitors in childhood solid tumors.

1 reference

https://api.crossref.org/works/10.1002%2FPBC.24547

21 January 2018

Vascular endothelial growth factor: a therapeutic target for tumors of the Ewing's sarcoma family

1 reference

https://api.crossref.org/works/10.1002%2FPBC.24547

21 January 2018

The anti-VEGF antibody bevacizumab potently reduces the growth rate of high-risk neuroblastoma xenografts

1 reference

https://api.crossref.org/works/10.1002%2FPBC.24547

21 January 2018

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FPBC.24547

21 January 2018

Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma.

1 reference

https://api.crossref.org/works/10.1002%2FPBC.24547

21 January 2018

Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FPBC.24547

21 January 2018

In vivo topoisomerase I inhibition attenuates the expression of hypoxia-inducible factor 1α target genes and decreases tumor angiogenesis

1 reference

https://api.crossref.org/works/10.1002%2FPBC.24547

21 January 2018

Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lun

1 reference

https://api.crossref.org/works/10.1002%2FPBC.24547

21 January 2018

Objective response of multiply recurrent low-grade gliomas to bevacizumab and irinotecan

1 reference

https://api.crossref.org/works/10.1002%2FPBC.24547

21 January 2018

Bevacizumab and irinotecan in the treatment of children with recurrent/refractory medulloblastoma.

1 reference

https://api.crossref.org/works/10.1002%2FPBC.24547

21 January 2018

Reducing irinotecan-associated diarrhea in children

1 reference

https://api.crossref.org/works/10.1002%2FPBC.24547

21 January 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1002%2FPBC.24547

21 January 2018

Irinotecan plus temozolomide for relapsed or refractory neuroblastoma.

1 reference

https://api.crossref.org/works/10.1002%2FPBC.24547

21 January 2018

Treatment of relapsed/refractory pediatric sarcomas with gemcitabine and docetaxel.

1 reference

https://api.crossref.org/works/10.1002%2FPBC.24547

21 January 2018

A phase I trial and pharmacokinetic study of aflibercept (VEGF Trap) in children with refractory solid tumors: a children's oncology group phase I consortium report

1 reference

https://api.crossref.org/works/10.1002%2FPBC.24547

21 January 2018

A phase 1 trial and pharmacokinetic study of cediranib, an orally bioavailable pan-vascular endothelial growth factor receptor inhibitor, in children and adolescents with refractory solid tumors

1 reference

https://api.crossref.org/works/10.1002%2FPBC.24547

21 January 2018

A phase I trial and pharmacokinetic study of sorafenib in children with refractory solid tumors or leukemias: a Children's Oncology Group Phase I Consortium report.

1 reference

https://api.crossref.org/works/10.1002%2FPBC.24547

21 January 2018

Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: a children's oncology group study

1 reference

https://api.crossref.org/works/10.1002%2FPBC.24547

21 January 2018

Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial

1 reference

https://api.crossref.org/works/10.1002%2FPBC.24547

21 January 2018

A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study

1 reference

https://api.crossref.org/works/10.1002%2FPBC.24547

21 January 2018

Identifiers

10.1002/PBC.24547

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/23630159

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

27 March 2018

http://europepmc.org/abstract/MED/23630159

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51030667&oldid=1566599704"